Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight, 2019 Market Research Report - ResearchAndMarkets.com

The "Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape is provided which includes the disease overview and Chronic Rhinosinusitis with Nasal Polyps treatment guidelines.

The assessment part of the report embraces, in depth Chronic Rhinosinusitis with Nasal Polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinusitis with Nasal Polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) pipeline report covers 6+ companies. Some of the key players include Pulmagen Therapeutics (GB 001), AnaptysBio (Etokimab) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Analytical Perspective

In-depth Chronic Rhinosinusitis with Nasal Polyps Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Chronic Rhinosinusitis with Nasal Polyps Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

2.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Disease Overview

2.2. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) History

2.3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Symptoms

2.4. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Causes

2.5. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Pathophysiology

2.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Diagnosis

3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Current Treatment Patterns

3.1. Treatment Guidelines

4. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)- Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Chronic Rhinosinusitis with Nasal Polyps companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Chronic Rhinosinusitis with Nasal Polyps Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Chronic Rhinosinusitis with Nasal Polyps Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Chronic Rhinosinusitis with Nasal Polyps -Products Analysis

6.1. Product Profiles

6.1.1. GB 001- Pulmagen Therapeutics

6.1.2. Etokimab- AnaptysBio

7. Recent Technologies

8. Chronic Rhinosinusitis with Nasal Polyps Key Companies

8.1. BioWa

8.2. Pfizer

8.3. Genentech, Inc.

8.4. Pulmagen Therapeutics

8.5. AnaptysBio, Inc.

8.6. Amgen

9. Chronic Rhinosinusitis with Nasal Polyps Key Products

9.1. Benralizumab

9.2. Botulinum Toxin Type A

9.3. PF-06817024

9.4. Xolair (omalizumab)

9.5. GB001

9.6. Etokimab

9.7. AMG 282

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Chronic Rhinosinusitis with Nasal Polyps - Unmet Needs

12. Chronic Rhinosinusitis with Nasal Polyps - Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sjaahc

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005886/en/